<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41865">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907724</url>
  </required_header>
  <id_info>
    <org_study_id>IDX-06A-007</org_study_id>
    <nct_id>NCT01907724</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and a Pharmacokinetic Enhancer When Administered in Combination in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and a Pharmacokinetic Enhancer When Administered in Combination in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idenix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Idenix Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential for a PK drug-drug interaction when
      IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination.
      Safety and tolerability will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of PK drug-drug interaction</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic measures of plasma drug exposure (AUCss, Ctrough and Cmax) of IDX719, simeprevir, TMC647055 and low-dose RTV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>14 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportions of subjects experiencing adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-7 = IDX719 150 mg once daily + ritonavir 30 mg once daily
Days 8-14 = IDX719 150 mg once daily + simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-7 = simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily
Days 8-14 = IDX719 150 mg once daily + simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>IDX719 will be supplied as a 50 mg tablet</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir will be supplied as 75 mg capsules</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC647055</intervention_name>
    <description>TMC647055 will be supplied as 150 mg capsules</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>RTV will be supplied as 80 mg/mL oral solution</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read and signed the written informed consent form (ICF) after the nature of the study
             has been fully explained.

          -  All subjects of childbearing potential must have agreed to use a double method of
             birth control (one of which must be a barrier) from Screening through at least 90
             days after the last dose of the study drug.

          -  Male subjects have agreed not to donate sperm from Day -1 through 90 days after the
             last dose of study drug.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Other clinically significant medical conditions or laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
